<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00446069</url>
  </required_header>
  <id_info>
    <org_study_id>MP-EG-002</org_study_id>
    <secondary_id>EudraCT number: 2006-006579-19</secondary_id>
    <nct_id>NCT00446069</nct_id>
  </id_info>
  <brief_title>A Efficacy and Safety Trial of Controlled Release (CR) Morphine in Cancer Patients</brief_title>
  <official_title>A Double-blind, Randomized, 2-way Cross-over, Phase II, Efficacy Trial in Cancer Patients to Assess the Overall Efficacy, Patient Preference, Morphine Related Side Effect Profile and Safety of the Egalet® Controlled Release Morphine Formulation 30-240 mg Once Daily Compared to MST Continus® 15-120 mg Twice Daily After 2 Weeks of Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Egalet Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Egalet Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the effect of Egalet® Morphine once daily compared
      to MST Continus twice daily on pain intensity and use of rescue medication for break through
      pain after 2 weeks of treatment in patients with pain due to cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Use of rescue medication</measure>
    <time_frame>2 weeks treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>2 weeks treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Pain</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Egalet® morphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MST Continus®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine Sulphate</intervention_name>
    <description>Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks</description>
    <arm_group_label>Egalet® morphine</arm_group_label>
    <arm_group_label>MST Continus®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has stable strong opioid use equipotent to 30-240 mg oral morphine
             sulphate daily for a minimum of 2 weeks prior to entering the run-in phase.

          -  The patient has opioid-sensitive pain caused by active cancer.

          -  The patient is aged minimum 18 years.

        Exclusion Criteria:

          -  The patient has a life expectancy less than 2 months.

          -  The patient has received chemotherapy or radiation therapy less than 4 weeks prior to
             entering run-in phase

          -  Patients with medical conditions contraindicating morphine treatment

          -  The patient has hepatic disease or impaired kidney function

          -  The patient is taking monoamine oxidase inhibitors (MAOIs) or has taken a MAOI within
             two weeks prior to entering baseline.

          -  The patient is taking other opioid agonists or antagonists, zidovudine or cimetidine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Andersen, MSc Pharm</last_name>
    <role>Study Director</role>
    <affiliation>Egalet A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 51</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 50</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 63</name>
      <address>
        <city>Bielsko-Biaia</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 60</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 62</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 61</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 64</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 65</name>
      <address>
        <city>Włocławek</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lithuania</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2007</study_first_submitted>
  <study_first_submitted_qc>March 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2007</study_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

